EXTENDED TREATMENT PROTOCOL FOR SUBJECTS CONTINUING TO BENEFIT FROM IBRUTINIB AFTER COMPLETION OF IBRUTINIB CLINICAL TRIALS
- Registry ID
- PCYC-1145-LT
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- PHARMACYCLICS SWITZERLAND GMBH
- Start date
- 2020-09-15
- Last update
- 2019-03-21
Conditions
- MULTIPLE MYELOMA
- FOLLICULAR LYMPHOMA
- DIFFUSE LARGE B-CELL LYMPHOMA
- GRAFT VS HOST DISEASE
Related clinical trials
- A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE VERSUS STANDARD OF CARE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY
- PHASE I DOSE ESCALATION STUDY OF LIPOSOMAL CURCUMIN IN RELAPSED REFRACTORY MULTIPLE MYELOMA
- Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
- A MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL, GROUP-SEQUENTIAL,
PHASE 3 STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF
INTRAVENOUS GAMMAGARD LIQUID (IMMUNE GLOBULIN INFUSION, 10%) FOR
PRIMARY INFECTION PROPHYLAXIS COMPARED WITH SECONDARY INFECTION
PROPHYLAXIS IN ADULT SUBJECTS WITH MULTIPLE MYELOMA RECEIVING B-CELL
MATURATION ANTIGEN×CD3¿DIRECTED BISPECIFIC ANTIBODY THERAPY
- AN OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL TO EVALUATE THE SAFETY, PHARMAKONETICS, AND ANTI-TUMOUR ACTIVITY OF TLN-121 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-LYMPHOMA AGENTS, IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS
- A PHASE 3, MULTICENTER, RANDOMIZED, OPEN LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF GOLCADOMIDE IN COMBINATION WITH RITUXIMAB (GOLCA + R) VS INVESTIGATOR'S CHOICE IN PARTICIPANTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF SYSTEMIC THERAPY (GOLSEEK-4)
View on source registry